

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**AUSTAR**

**奥星**

**Austar Lifesciences Limited**

**奥星生命科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6118)**

**INSIDE INFORMATION –  
UPDATE ON FILING FOR INSOLVENCY BY NON-WHOLLY OWNED  
SUBSIDIARIES**

This announcement is made by Austar Lifesciences Limited (“**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 3 August 2023 (“**Announcement**”) in relation to, among others, the Insolvency Filings made by H+E Pharma and S-Tec under self-administration (debtor in possession) proceedings in Germany on 3 August 2023 (German time). Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board wishes to update the Shareholders and potential investors that based on the information currently available to the Board, the Group is expected to record a loss on the Insolvency Filings of approximately RMB60 million in the second half of the year ending 31 December 2023. Such estimation is made only based on the preliminary assessment by the management of the Company and is not based on any figure or information which has been audited or reviewed by the Company’s auditors and may be subject to adjustments and changes.

Further announcement(s) regarding the Insolvency Filings will be made by the Company as and when appropriate.

**Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Austar Lifesciences Limited**  
**Ho Kwok Keung, Mars**  
*Chairman and Chief Executive Officer*

Hong Kong, 29 August 2023

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.*